IMT Header

Short Courses*

Tuesday, August 25

 

Targeting the Cancer Mutanome 

TOPICS AND SPEAKERS:


Targeting the Cancer Mutanome
Emerging sequencing and bioinformatics technologies are now giving researchers new perspectives on the mutations in patient specific antigens, now collectively known as the cancer mutanome. Our dinner short course offers academic and industry perspectives on the analytical and computational methods used to identify neo-epitopes within a mutanome that are candidates for therapeutic intervention – and the potential applications of this knowledge in patient diagnostics and immunotherapy. An open discussion format will allow those working in this space to share insights and experiences on how to advance this new field into clinical practice.

Background and Update on Current Science
Radvanyi LaszloCourse Leader: Laszlo Radvanyi, Ph.D., Chief Scientific Officer, Lion Biotechnologies
An overview on the emerging field of neo-antigen (mutanome) targeting will be presented. This overview will summarize the current approaches used to deduce cancer neo-antigen epitopes for immunological targeting, specific examples of how neo-antigen targeting is being used already in cancer immunotherapy, some of the obstacles being faced in the field, and the impact of neo-antigen targeting will have in the future of immunotherapy.

Neo-antigens in Cancer Immunotherapy
Lelia DelamarreLelia Delamarre, Ph.D., Scientist, Cancer Immunology, Genentech (Confirmed)
Tumors accumulate mutations, which can be recognized as foreign and induce immune responses. We developed a novel strategy to identify neoepitopes by combining whole-exome sequencing and mass spectrometry analysis, along with structural prediction for discovery of immunogenic antigens. This information can be used for the immuno-monitoring of cancer patients, and help identify which patients will benefit from immunotherapy. Finally this knowledge could be exploited for the design of personalized vaccines.

Identifying Suitable Neoepitopes – Seeing Through the Fog of Suppression
Pramod SrivastavaPramod Srivastava, M.D., Ph.D., Professor, Immunology and Medicine, University of Connecticut School of Medicine; Director, Carole and Ray Neag Comprehensive Cancer Center (Confirmed)
Results of experiments, which do or do not eliminate the effect of immune suppression, while screening for immunogenic protective neoepitopes, shall be presented and discussed.

What T Cells See on Human Cancer
Marit van BuurenMarit van Buuren, MSc, Ph.D. Student, Cancer Immunology, Netherlands Cancer Institute (Confirmed; Unpublished data)
Human tumors are characterized by large numbers of mutations, of which many hundreds can be contained within expressed genes, resulting in so-called “neo-antigens”. The immune recognition of these antigens is hypothesized to be of significant importance to the activity of clinically used immunotherapeutics in melanoma. With the use of in-house developed technologies to monitor T cell reactivity, we have shown that the T cell recognition of neo-antigens is a common feature in human melanoma.

Thursday, August 27

 

Adoptive Therapy with CAR T Cells 

Laurence J.N. Cooper, M.D., Ph.D., Grant Taylor, W.W. Sutow and Margaret Sullivan Distinguished Professor in Pediatrics; MDACC Section Chief, Cell Therapy, Children’s Cancer Hospital, Division of Pediatrics (Unit 907); Associate Director, CCIR; Director, Immunology Laboratory of Physician Scientists, Department of Immunology, MD Anderson Cancer Center 

Additional Instructors to be Announced 

Adoptive cell therapy (ACT) is causing a great deal of excitement in the research community given its ability to use a patient’s immune system to recognize and attack disease cells. The current frontrunner for ACT is chimeric antigen receptor (CAR) T cells, which allows for more potency than has been seen in many other immunotherapies. At this short course, researchers working with CAR T cells will address:

  • Genetically modified T cells from immunology to immunotherapy
  • Managing toxicity-related side-effects
  • Improving platforms and processes
  • Novel CAR T cell designs


*Separate registration is required.